Gland Pharma has executed a strategic Manufacturing and Supply Agreement (MSA) with one of the leading global pharmaceutical companies for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets. The partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.
The portfolio comprises a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules and pre-filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive 'one-stop' solution to its partner.
The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 stock keeping units (SKUs) to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be around $90-100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
